A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer

Stopped early · Phase 2

Conditions studied: Endometrial Neoplasms

In brief

This study will investigate the individual safety and efficacy of two dual PI3K/mTOR inhibitors in patients with recurrent endometrial cancer.

Key facts

Study ID

NCT01420081

Run by

Pfizer

People needed

67

Starts

2012-01-19

Expected to finish

2015-12-25

Last updated by the study team

2019-01-08

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Recurrent endometrial carcinoma
• Disease progression following one or two lines of prior treatment with platinum containing chemotherapy
• Tumor tissue available at time of screening for PI3K analysis
• Adequate performance status
• Adequate glucose control, bone marrow, kidney, liver, and heart function

You may not qualify if…

• More than 2 prior cytotoxic chemo regimens for endometrial carcinoma
• Prior therapy with an agent known to be a PI3K, and or mTOR and or AKT inhibitor
• Active brain metastases

Where it is running

• University of Alabama at Birmingham, IDS Pharmacy — Birmingham, Alabama, United States
• University of Alabama at Birmingham — Birmingham, Alabama, United States
• University of California Medical Center — La Jolla, California, United States
• Moores UC San Diego Cancer Center — La Jolla, California, United States
• University of California Medical Center — San Diego, California, United States
• Mercy Hospital — Miami, Florida, United States
• Mercy Research Institute — Miami, Florida, United States
• University of Chicago Medical Center — Chicago, Illinois, United States
• University of Chicago Medicine Comprehensive Cancer Center at Silver Cross Hospital — New Lenox, Illinois, United States
• University of Kansas — Fairway, Kansas, United States
• University of Kansas Hospital — Kansas City, Kansas, United States
• University of Kansas Cancer Center and Medical Pavilion — Westwood, Kansas, United States
• Mary Bird Perkins Cancer Center at St. Tammany Parish Hospital — Covington, Louisiana, United States
• Women's Cancer Care — Covington, Louisiana, United States
• Women's Cancer Care — Metairie, Louisiana, United States
• Massachusetts General Hospital — Boston, Massachusetts, United States
• Brigham and Women's Hospital — Boston, Massachusetts, United States
• Dana Farber Cancer Institute — Boston, Massachusetts, United States
• University of Michigan — Ann Arbor, Michigan, United States
• University of New Mexico Cancer Center — Albuquerque, New Mexico, United States
• Peter MacCallum Cancer Centre, Division of Cancer Madicine — East Melbourne, Victoria, Australia
• Foothills Medical Center — Calgary, Alberta, Canada
• Tom Baker Cancer Centre — Calgary, Alberta, Canada
• British Columbia Cancer Agency - Vancouver Centre — Vancouver, British Columbia, Canada
• University of Alabama at Birmingham — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.